EyePoint Pharmaceuticals, Inc.
EYPT
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treā¦ read more
Healthcare
Biotechnology
20 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$18.03
Price-1.29%
-$0.24
1Y
Price
Market Cap
$1.237b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-6123.8%
EBITDA Margin-6183.4%
Net Profit Margin-6226.9%
Free Cash Flow Margin-6123.8%
EBITDA Margin-6183.4%
Net Profit Margin-6226.9%
Free Cash Flow MarginRevenue
$42.340m
-2.2%
1y CAGR+1.0%
3y CAGR+3.8%
5y CAGREarnings
-$205.752m
-57.2%
1y CAGR-37.1%
3y CAGR-46.6%
5y CAGREPS
-$2.99
-28.9%
1y CAGR-7.6%
3y CAGR-14.4%
5y CAGRBook Value
$200.182m
$251.695m
Assets$51.513m
Liabilities$21.301m
DebtDebt to Assets
8.5%
-0.1x
Debt to EBITDAFree Cash Flow
-$213.590m
-64.0%
1y CAGR-2656.1%
3y CAGR-2000.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company